These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29411309)

  • 41. Use of Organs From Hepatitis C Virus-Positive Donors for Uninfected Recipients: A Potential Cost-Effective Approach to Save Lives?
    Trotter PB; Summers DM; Ushiro-Lumb I; Robb M; Bradley JA; Powell J; Watson CJE; Neuberger J
    Transplantation; 2018 Apr; 102(4):664-672. PubMed ID: 29166338
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study.
    Mahmoud IM; Elhabashi AF; Elsawy E; El-Husseini AA; Sheha GE; Sobh MA
    Am J Kidney Dis; 2004 Jan; 43(1):131-9. PubMed ID: 14712436
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease.
    Kwo PY; Badshah MB
    Curr Opin Organ Transplant; 2015 Jun; 20(3):235-41. PubMed ID: 25944238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents?
    Dall'Agata M; Gramenzi A; Biselli M; Bernardi M
    World J Gastroenterol; 2014 Jul; 20(28):9253-60. PubMed ID: 25071318
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management.
    Jadoul M; Berenguer MC; Doss W; Fabrizi F; Izopet J; Jha V; Kamar N; Kasiske BL; Lai CL; Morales JM; Patel PR; Pol S; Silva MO; Balk EM; Gordon CE; Earley A; Di M; Martin P
    Kidney Int; 2018 Oct; 94(4):663-673. PubMed ID: 30243313
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fibrosing cholestatic hepatitis after kidney transplantation from HCV-viremic donors to HCV-negative recipients: A unique complication in the DAA era.
    Kapila N; Al-Khalloufi K; Bejarano PA; Vanatta JM; Zervos XB
    Am J Transplant; 2020 Feb; 20(2):600-605. PubMed ID: 31448549
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens.
    Puenpatom A; Hull M; McPheeters J; Schwebke K
    Clin Drug Investig; 2017 Jul; 37(7):687-697. PubMed ID: 28386819
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
    Mansour M; Hill L; Kerr J
    Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatitis C and renal transplantation: the controversy continues.
    Goral S; Helderman JH
    Kidney Int; 1998 May; 53(5):1419-20. PubMed ID: 9573562
    [No Abstract]   [Full Text] [Related]  

  • 50. Hepatitis C therapy with long term remission after renal transplantation.
    Bunnapradist S; Fabrizi F; Vierling J; Martin R; Moudgil A; Kamil E; Jordan S
    Int J Artif Organs; 2002 Dec; 25(12):1189-93. PubMed ID: 12518964
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of Recipient Hepatitis C Status on Outcomes of Deceased Donor Kidney Transplantation.
    Yuan Q; Hong S; Perez-Ortiz A; Roth E; Chang DC; Madsen JC; Elias N
    J Am Coll Surg; 2020 Jun; 230(6):853-861.e3. PubMed ID: 32035979
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.
    Wyles DL; Sulkowski MS; Dieterich D
    Clin Infect Dis; 2016 Jul; 63 Suppl 1(Suppl 1):S3-S11. PubMed ID: 27363438
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatitis C Virus Infection in Kidney Transplant Patients: Current Treatment Options.
    Dzekova-Vidimliski P; Sikole A
    Exp Clin Transplant; 2017 Dec; 15(6):587-593. PubMed ID: 29219790
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey.
    Shaffer AA; Thomas AG; Bowring MG; Van Pilsum Rasmussen SE; Cash A; Kucirka LM; Alqahtani SA; Gurakar A; Sulkowski MS; Cameron AM; Segev DL; Durand CM
    Transpl Infect Dis; 2018 Dec; 20(6):e12982. PubMed ID: 30144258
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Direct-acting antivirals and hepatitis B virus (HBV) reactivation in co-infected HBV/HCV kidney-transplant recipients.
    Pol S; Marion O; Vallet-Pichard A; Meritet JF; Sauné K; Alric L; Kamar N
    Transpl Infect Dis; 2018 Jun; 20(3):e12864. PubMed ID: 29512231
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
    Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
    Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Negativization of viremia prior to liver transplant reduces early allograft dysfunction in hepatitis C-positive recipients.
    Martini S; Tandoi F; Terzi di Bergamo L; Strona S; Lavezzo B; Sacco M; Maione F; Gonella F; Strignano P; Dell Olio D; Salizzoni M; Saracco GM; Romagnoli R
    Liver Transpl; 2017 Jul; 23(7):915-924. PubMed ID: 28422425
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
    Ridruejo E; Garcia-Agudo R; Mendizabal M; Aoufi-Rabih S; Dixit V; Silva M; Fabrizi F
    Nefrologia (Engl Ed); 2020; 40(1):46-52. PubMed ID: 31229261
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era.
    Cacoub P; Vautier M; Desbois AC; Lafuma A; Saadoun D
    Liver Int; 2017 Dec; 37(12):1805-1813. PubMed ID: 28467688
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of Post-Liver Transplant Recurrence of Hepatitis C.
    Taylor J; Cox-North P; Landis CS
    Drugs; 2016 Dec; 76(18):1711-1717. PubMed ID: 27878476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.